Yoshiya Tanaka

2 months ago | onlinelibrary.wiley.com | Koshiro Sonomoto |Japan JAPAN |Yoshiya Tanaka

1 Introduction As Japan leads the world in population aging, the healthcare landscape is facing unprecedented challenges, particularly in the management of chronic diseases such as rheumatoid arthritis (RA). In Japan, demographic change has led to a marked increase in the proportion of RA patients aged 65 years and older, many of whom are further burdened by comorbidities such as chronic kidney disease, cardiovascular disease, lung disease, and a history of serious infections [1].

2 months ago | onlinelibrary.wiley.com | Satoshi KUBO |Yoshiya Tanaka

1 Introduction Precision medicine represents an aspirational target in contemporary medical practice for numerous diseases [1, 2]. In the United States, a national initiative is advancing precision medicine as the foundational strategy for treatment, employing molecular targeted therapeutics for malignant tumors.

Jan 20, 2025 | lupus.bmj.com | Yoshiya Tanaka |Yusuke Miyazaki |Shintaro Hirata |Katsuhide Kusaka

In clinical practice, a lupus low disease activity state (LLDAS) has been proposed as an alternative treatment target for patients with SLE. LLDAS is associated with reduced accrual of organ damage and improvements in quality of life. Patients with SLE in LLDAS experienced a residual disease burden, especially in pain and fatigue, that was associated with activity impairment.

Jan 6, 2025 | nature.com | Martin Pehrsson |Anne-Christine Bay-Jensen |Morten Asser Karsdal |Bent Deleuran |Tue W. Kragstrup |Satoshi KUBO | +2 more

AbstractUnderstanding how inflammatory cytokines influence profibrogenic wound healing responses in fibroblasts is important for understanding the pathogenesis of fibrosis. TNF-α and IL-13 are key cytokines in Th1 and Th2 immune responses, respectively, while TGF-β1 is the principal pro-fibrotic mediator.

Sep 1, 2024 | nature.com | Satoshi KUBO |Yoshiya Tanaka

Immune health has been considered impossible to assess through the use of traditional biomarkers. The newly devised immune health metric (IHM) integrates diverse biological data to quantify immune function, offering a comprehensive indicator for the evaluation of immune health. The potential of the IHM to distinguish healthy individuals from patients with monogenic or polygenic immune-mediated diseases might lead to revolutionary changes in treatment strategies for rheumatic diseases.